Selected research
Industry Growth & Trends
Global Imatinib Drugs Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Imatinib Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Imatinib Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Imatinib Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Imatinib Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Imatinib Drugs market include Teva, Sun Pharmaceuticals, Sanofi S.A., Novartis, Glenmark Pharmaceuticals Ltd., Viatris, Dr. Reddy's Laboratories, Cipla Inc. and Apotex Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Imatinib Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Imatinib Drugs market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Imatinib Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Imatinib Drugs.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Imatinib Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Imatinib Drugs Market by Company
Teva
Sun Pharmaceuticals
Sanofi S.A.
Novartis
Glenmark Pharmaceuticals Ltd.
Viatris
Dr. Reddy's Laboratories
Cipla Inc.
Apotex Inc.
Imatinib Drugs Segment by Type
Capsules
Tablets
Imatinib Drugs Segment by Application
Hospitals
Drug Stores
Others
Imatinib Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Imatinib Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Imatinib Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Imatinib Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Imatinib Drugs companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Capsules
- Tablets
Applications
- Hospitals
- Drug Stores
- Others
Companies covered
- Teva
- Sun Pharmaceuticals
- Sanofi S.A.
- Novartis
- Glenmark Pharmaceuticals Ltd.
- Viatris
- Dr. Reddy's Laboratories
- Cipla Inc.
- Apotex Inc.
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Imatinib Drugs Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Imatinib Drugs Market Size by Region (2021-2032)
- 1.4.1 Global Imatinib Drugs Market Size by Region (2021-2026)
- 1.4.2 Global Imatinib Drugs Market Size by Region (2027-2032)
- 1.5 Key Regions Imatinib Drugs Market Size (2021-2032)
- 1.5.1 North America Imatinib Drugs Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Imatinib Drugs Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Imatinib Drugs Market Size Growth Rate (2021-2032)
- 1.5.4 South America Imatinib Drugs Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Imatinib Drugs Market Size Growth Rate (2021-2032)
2 Imatinib Drugs Market by Type
- 2.1 Type Introduction
- 2.1.1 Capsules
- 2.1.2 Tablets
- 2.2 Global Imatinib Drugs Market Size by Type
- 2.2.1 Global Imatinib Drugs Market Size Overview by Type (2021-2032)
- 2.2.2 Global Imatinib Drugs Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Imatinib Drugs Market Size Forecasted by Type (2027-2032)
- 2.3 Global Imatinib Drugs Market Size by Regions
- 2.3.1 North America Imatinib Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Imatinib Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Imatinib Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Imatinib Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Imatinib Drugs Market Size Breakdown by Type (2021-2026)
3 Imatinib Drugs Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospitals
- 3.1.2 Drug Stores
- 3.1.3 Others
- 3.2 Global Imatinib Drugs Market Size by Application
- 3.2.1 Global Imatinib Drugs Market Size Overview by Application (2021-2032)
- 3.2.2 Global Imatinib Drugs Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Imatinib Drugs Market Size Forecasted by Application (2027-2032)
- 3.3 Global Imatinib Drugs Market Size by Regions
- 3.3.1 North America Imatinib Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Imatinib Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Imatinib Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Imatinib Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Imatinib Drugs Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Imatinib Drugs Industry Trends
- 4.2 Imatinib Drugs Industry Drivers
- 4.3 Imatinib Drugs Industry Opportunities and Challenges
- 4.4 Imatinib Drugs Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Imatinib Drugs Revenue (2021-2026)
- 5.2 Global Imatinib Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Imatinib Drugs Key Company Headquarters & Area Served
- 5.4 Global Imatinib Drugs Company, Product Type & Application
- 5.5 Global Imatinib Drugs Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Imatinib Drugs Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Imatinib Drugs Players Market Share by Revenue in 2025
- 5.6.3 2025 Imatinib Drugs Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Teva
- 6.1.1 Teva Company Information
- 6.1.2 Teva Business Overview
- 6.1.3 Teva Imatinib Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Teva Imatinib Drugs Product Portfolio
- 6.1.5 Teva Recent Developments
- 6.2 Sun Pharmaceuticals
- 6.2.1 Sun Pharmaceuticals Company Information
- 6.2.2 Sun Pharmaceuticals Business Overview
- 6.2.3 Sun Pharmaceuticals Imatinib Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Sun Pharmaceuticals Imatinib Drugs Product Portfolio
- 6.2.5 Sun Pharmaceuticals Recent Developments
- 6.3 Sanofi S.A.
- 6.3.1 Sanofi S.A. Company Information
- 6.3.2 Sanofi S.A. Business Overview
- 6.3.3 Sanofi S.A. Imatinib Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Sanofi S.A. Imatinib Drugs Product Portfolio
- 6.3.5 Sanofi S.A. Recent Developments
- 6.4 Novartis
- 6.4.1 Novartis Company Information
- 6.4.2 Novartis Business Overview
- 6.4.3 Novartis Imatinib Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Novartis Imatinib Drugs Product Portfolio
- 6.4.5 Novartis Recent Developments
- 6.5 Glenmark Pharmaceuticals Ltd.
- 6.5.1 Glenmark Pharmaceuticals Ltd. Company Information
- 6.5.2 Glenmark Pharmaceuticals Ltd. Business Overview
- 6.5.3 Glenmark Pharmaceuticals Ltd. Imatinib Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Glenmark Pharmaceuticals Ltd. Imatinib Drugs Product Portfolio
- 6.5.5 Glenmark Pharmaceuticals Ltd. Recent Developments
- 6.6 Viatris
- 6.6.1 Viatris Company Information
- 6.6.2 Viatris Business Overview
- 6.6.3 Viatris Imatinib Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Viatris Imatinib Drugs Product Portfolio
- 6.6.5 Viatris Recent Developments
- 6.7 Dr. Reddy's Laboratories
- 6.7.1 Dr. Reddy's Laboratories Company Information
- 6.7.2 Dr. Reddy's Laboratories Business Overview
- 6.7.3 Dr. Reddy's Laboratories Imatinib Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Dr. Reddy's Laboratories Imatinib Drugs Product Portfolio
- 6.7.5 Dr. Reddy's Laboratories Recent Developments
- 6.8 Cipla Inc.
- 6.8.1 Cipla Inc. Company Information
- 6.8.2 Cipla Inc. Business Overview
- 6.8.3 Cipla Inc. Imatinib Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Cipla Inc. Imatinib Drugs Product Portfolio
- 6.8.5 Cipla Inc. Recent Developments
- 6.9 Apotex Inc.
- 6.9.1 Apotex Inc. Company Information
- 6.9.2 Apotex Inc. Business Overview
- 6.9.3 Apotex Inc. Imatinib Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Apotex Inc. Imatinib Drugs Product Portfolio
- 6.9.5 Apotex Inc. Recent Developments
7 North America
- 7.1 North America Imatinib Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Imatinib Drugs Market Size by Country (2021-2026)
- 7.3 North America Imatinib Drugs Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Imatinib Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Imatinib Drugs Market Size by Country (2021-2026)
- 8.3 Europe Imatinib Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Imatinib Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Imatinib Drugs Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Imatinib Drugs Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Imatinib Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Imatinib Drugs Market Size by Country (2021-2026)
- 10.3 South America Imatinib Drugs Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Imatinib Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Imatinib Drugs Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Imatinib Drugs Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst